Med24
metabolic-therapy 19. 10. 2026 • 2 min read • Clinical rheumatology (PubMed)

Hepatic steatosis and liver stiffness in patients with gout: a controlled cross-sectional elastography study.

BACKGROUND/OBJECTIVE: Gout shares cardiometabolic risk factors with metabolic dysfunction-associated steatotic liver disease (MASLD). We aimed to compare elastography-defined hepatic steatosis and liver stiffness between patients with gout and metabolically stringent controls, and to identify independent determinants...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This controlled cross-sectional study examined hepatic steatosis and liver stiffness in patients with gout compared to metabolically stringent controls. The study, conducted from April 2024 to January 2026, involved 201 patients with gout and 80 controls without hypertension, diabetes mellitus, chronic kidney disease, or coronary artery disease.

Key Clinical Findings

Patients with gout demonstrated significantly higher controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) values. Unadjusted analyses revealed a higher odds of hepatic steatosis and increased liver stiffness in the gout group. Multivariable analysis indicated that BMI and alanine aminotransferase (ALT) were principal determinants of CAP, while BMI and age independently predicted continuous LSM.

Sponsored content

Study Conclusions

Gout status was not independently associated with CAP, continuous LSM, hepatic steatosis, or increased liver stiffness after adjustment for age, BMI, and cardiometabolic covariates. The study suggests that non-invasive liver assessment in gout should be guided by cardiometabolic risk profile rather than the diagnosis of gout itself.

Original Scientific Source
Clinical rheumatology (PubMed)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.
metabolic-therapy

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

10. 11. 2026 Read article →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement